Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 14/20 | 0.59 |
| ▸ | RARB | P10826 | 12/20 | 0.59 |
| ▸ | RARG | P13631 | 11/20 | 0.59 |
| ▸ | RXRB | P28702 | 9/20 | 0.59 |
| ▸ | RXRG | P48443 | 6/20 | 0.59 |
| ▸ | RARA | P10276 | 9/20 | 0.56 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.55 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9185760 | 0.82 | RXRA (0.55) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL8733241 | 0.82 | RARB (0.83) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL846110 | 0.80 | RARB (0.81) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL2195224 | 0.80 | RXRA (0.66) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL29827631 | 0.80 | RARB (0.81) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL1022234 | 0.79 | RXRA (0.63) | RXRARARBRARGRXRBRXRG | |
| Hydrochloric Acid SCHEMBL9120757 | 0.79 | RARB (0.78) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL2195010 | 0.79 | RXRA (0.63) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL2143247 | 0.79 | KDM4E (0.41) | RXRARARBRARGRXRBRXRG | |
| SCHEMBL1446400 | 0.79 | KDM4E (0.41) | RXRARARBRARGRXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8765719-B2 | Therapeutic drug for adult T-cell leukemia | KAGOSHIMA UNIVERSITY (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-2345409-A1 | THERAPEUTIC AGENT FOR ADULT T-CELL LEUKEMIA | Kagoshima University (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | KAGOSHIMA UNIVERSITY (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172185-A1 | THERAPEUTIC DRUG FOR ADULT T-CELL LEUKEMIA | CBR3, CD47, ATL3 | RXRA 1135/4885RARB 2945/4885RARG 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.